Moreover, trastuzumab, a monoclonal antibody directed against the extracellular HER2 domain, which has effectively been used in breast cancer patients with HER2 overexpression, may be effective in patients with NSCLC that harbor HER2 gene mutations (21). This evidence concerns the gene ERBB2 and breast carcinoma.